Abstract:956 Background: Most patients with metastatic cancer will eventually succumb to their disease despite an initial response to chemotherapy. To enhance treatment efficacy, chemotherapy has been combined with cytokines, often with disappointing results. Another example is “Immunocentric Chemoimmunotherapy,” with primary focus placed on immunotherapy, with chemotherapy as an immunomodulator. We have developed a novel strategy termed “Chemocentric Chemoimmunotherapy,” where chemotherapy plays the central role, with immunotherapy as a chemosensitizer. The rationale is the ability of activated T cells to secret multiple cytokines, which may regulate gene expression in tumor cells. Methods: Human CD4+ T cells were isolated and activated with anti-CD3/anti-CD28 mAb. Tumor cells were presensitized with activated CD4+ T cells (aCD4), followed by treatment with various chemotherapy. Cell viability and apoptosis were determined. Transwell system was used to assess contribution of cell-cell contact vs. soluble factor(s). Results: Presensitization of A375 melanoma cells with aCD4 synergistically enhanced the cytotoxic effects of chemotherapy. Cell viability (CV) was 75% (+SD: 0.11) and 90% (+SD: 0.26) after treatment with temozolomide (TMZ) alone or with aCD4 alone, respectively. However, CV in the experimental group was 7% (+SD: 0.02). This synergistic effect was also observed with other melanoma cell lines, nonmelanoma tumor cell lines, and other chemotherapy. Two breast, one prostate, and one colon cancer cell lines were presensitized with aCD4, followed by treatment with paclitaxel, carboplatin, or 5-FU. Consistent synergistic effect was seen in each case. For example, CV in MDA-MB-231 breast cancer cells treated with paclitaxel alone or aCD4 alone was 93% (+SD: 0.16) and 52% (+SD: 0.10), respectively. However, CV in the experimental group was 8% (+SD: 0.18). The same synergism was observed in DU145 prostate cancer cell line treated with carboplatin. CV in the carboplatin-treated group and aCD4-treated group was 100% (+ SD: 0.13) and 75% (+SD: 0.14), respectively; while CV of the experimental group was 5% (+SD: 0.19). The rate of apoptosis in cells treated with both TMZ and aCD4 was 20 times higher than in cells treated with only TMZ or aCD4. This effect was due entirely to soluble factors. The aCD4 was found to secret large amounts of multiple cytokines. Preliminary data showed that IFN-γ might not be the major cytokine mediating the observed effect. Conclusion: Presensitization of tumor cells with aCD4 synergistically enhanced the cytotoxic effect of chemotherapy. This effect was completely dependent on soluble factors, most likely cytokines. We are in the process of elucidating the mechanisms underlying this dramatic synergy.

Mechanisms involved in synergistic anticancer effects of anti-4-1BB and cyclophosphamide therapy

Differential Requirements for CD4+ T Cells in the Efficacy of the Anti-Pd-1+lag-3 and Anti-Pd-1+ctla-4 Combinations in Melanoma Flank and Brain Metastasis Models.

Combination of 4-1BB agonist and PD-1 antagonist promotes antitumor effector/memory CD8 T cells in a poorly immunogenic tumor model

Targeting 4-1BB and PD-L1 induces potent and durable antitumor immunity in B-cell lymphoma

Therapeutic Efficacy of 4-1BB Costimulation Is Abrogated by PD-1 Blockade in a Model of Spontaneous B-cell Lymphoma

Combination immunotherapy with 4-1BB activation and PD-1 blockade enhances antitumor efficacy in a mouse model of subcutaneous tumor

IFN-γ producing T cells contribute to the increase of myeloid derived suppressor cells in tumor-bearing mice after cyclophosphamide treatment

Proinflammatory allogeneic dendritic cells enhance the therapeutic efficacy of systemic anti-4-1BB treatment

Anti-4-1BB scFv immunogene therapy and low dose cyclophosphamide exhibit a synergistic antitumor effect in established murine lung tumors.

Combination therapy with cisplatin and anti-4-1BB: synergistic anticancer effects and amelioration of cisplatin-induced nephrotoxicity

Polyfunctional CD4+ T Cells Are Essential for Eradicating Advanced B-cell Lymphoma after Chemotherapy

Immunotherapy of cancer with 4-1BB

Divergent effects of 4-1BB antibodies on antitumor immunity and on tumor-reactive T-cell generation

4-1BB Agonism Combined with PD-L1 Blockade Increases the Number of Tissue-Resident CD8+T Cells and Facilitates Tumor Abrogation

4-1BB agonism: adding the accelerator to cancer immunotherapy

"Chemocentric" Chemoimmunotherapy: Presensitization of Tumor Cells with Activated Cd4+T Cells Synergistically Enhances the Cytotoxic Effect of Chemotherapy

Abstract 4977: Immunogenic Chemotherapy Synergize PD-1 Blockade by Enhancing Dendritic Cells Infiltration in Triple-Negative Breast Cancer (TNBC)

Anti-4-1BB immunotherapy enhances systemic immune effects of radiotherapy to induce B and T cell-dependent anti-tumor immune activation and improve tumor control at unirradiated sites

Combinatorial immunotherapy induces tumor-infiltrating CD8+ T cells with distinct functional, migratory, and stem-like properties

Synergizing CXCL9 with BRD4‐PROTAC Using Nanochaperone Boosts Robust T Cell‐Dependent Antitumor Immune Responses for Cancer Immunotherapy

Enhancing the Antitumor Response of CD8+ T Cells by 4-1BB (CD137) Co-Stimulation with Distinct Inactivation of the Type 2 Adenosine Receptors